Louveciennes, France – December 7, 2015 – Aptar Pharma, a global solution provider of innovative and proven aerosol, injection and spray delivery systems for biotech, healthcare and pharma products, will present its latest innovation, DF30Plus with COCe, at the Drug Delivery to the Lungs (DDL) scientific conference in Edinburgh, Scotland from December 9 to December 11, 2015. This new DF30Plus metering valve version incorporates a Cyclic-Olefin-Copolymer (COC) neck gasket to further enhance its performance. It is the result of continuous improvement to today’s world leading DF30 technology platform. Aptar Pharma, a worldwide leader in innovative and proven inhalation drug delivery devices for Asthma and Chronic Obstructive Pulmonary Disease (COPD) Aptar Pharma is the worldwide leader in aerosol metering valves for pMDIs for the treatment of Asthma and COPD. Aptar Pharma’s metering valves are considered the “go to” solution for major branded pharmaceutical companies and generic producers across the globe. Each year, several hundred million metering valves are produced in Aptar Pharma’s three manufacturing facilities strategically located across Europe and Asia. Aptar Pharma is the only metering valve supplier that designs, develops and manufactures its own elastomer gaskets – a key component of the valve – within its unique in-house Elastomer Center. DF30Plus with COCe: ultra-clean, robust and versatile Aptar Pharma’s DF30 metering valve technology platform has been the industry gold standard for more than 20 years and we are constantly striving to optimize our DF30 product offering. COC is a well-known and characterized material used for injectable drug containers. COCe is a specific version of COC that has unique elastomeric properties while being ultraclean and inert. The new version of DF30Plus that incorporates a neck gasket manufactured with COCe offers several key benefits: – Step change improvement as a barrier to leakage – Ultra low extractible level – Compatibility across a wider range of drug formulations, including ethanol-containing formulations – Suitable for all pMDI filling technologies – Robust design for accurate and consistent performance 1/2 PRESS RELEASE – PRESS RELEASE – PRESS RELEASE – PRESS RELEASE – PRESS RELEASE – PRESS RELEASE – PRESS RELEASE “Thanks to the introduction of our novel COCe within our DF30 Valve Technology Platform, Aptar Pharma is able to offer a series of key advantages to meet the evolving needs of our customers; including improved compatibility with both EtOH containing and dry drug formulations, superior cleanliness and improved leakage barrier characteristics which result in a more robust and less crimp sensitive manufacturing process,” said Chris Baron, Associate Director, Business Development, for Aptar Pharma.